Standard criteria for relapse are needed in obsessive-compulsive disorder

Depression and Anxiety

Volumn 21, Issue 1, 2005, Pages 1-8

  Simpson, Helen Blair ^a,b   Franklin, Martin E ^c   Cheng, Jianfeng ^a,b   Foa, Edna B ^c   Liebowitz, Michael R ^a,b  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Clomipramine; Cognitive behavioral therapy; Exposure and ritual prevention; Obsessive compulsive disorder; Randomized controlled trial

Indexed keywords

CLOMIPRAMINE; FLUOXETINE; FLUVOXAMINE; PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ADULT; ANALYTIC METHOD; ARTICLE; BEHAVIOR THERAPY; CLINICAL TRIAL; COGNITIVE THERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DRUG EFFICACY; EXPOSURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSESSIVE COMPULSIVE DISORDER; POST HOC ANALYSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RELAPSE; RISK ASSESSMENT; STANDARD;

ANTIDEPRESSIVE AGENTS, TRICYCLIC; CLOMIPRAMINE; COGNITIVE THERAPY; COMBINED MODALITY THERAPY; HUMANS; OBSESSIVE-COMPULSIVE DISORDER; RECURRENCE; STEREOTYPIC MOVEMENT DISORDER;

EID: 18144369637     PISSN: 10914269     EISSN: None     Source Type: Journal    
DOI: 10.1002/da.20052     Document Type: Article

References (24)

1. Eisen JL, Goodman WK, Keller MB, Warshaw MG, DeMarco LM, Luce DD, Rasmussen SA. 1999. Patterns of remission and relapse in obsessive-compulsive disorder: A 2-year prospective study. J Clin Psychiatry 60:346-351.
2. Foa EB, Kozak MJ. 1996. Psychological treatment for obsessive-compulsive disorder. In: Mavissakalian MR, Prien RF, editors. Long-term treatments of anxiety disorders. Washington, DC: American Psychiatric Press, Inc. p 285-309.
3. Foa EB, Liebowitz MR, Kozak MJ, Davies S, Campeas R, Franklin ME, Huppert JD, Kjernisted K, Rowan V, Schmidt AB, Simpson HB, Tu X. 2005. Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder. Am J Psychiatry 162:151-161.
4. Frank E, Prien RF, Jarret RB, Keller MB, Kupfer DJ, Lavori PW, Rush AJ, Weissman MM. 1991. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Arch Gen Psychiatry 48:851-855.
5. Franklin ME, Foa EB. 2002. Cognitive behavioral treatments for obsessive compulsive disorder. In: Nathan PE, Gorman JM, editors. A guide to treatments that work (2nd ed.). London: Oxford University Press, p 367-386.
6. Goodman WK, Price LH, Rasmussen SA, Mazure C, Delgado P, Heninger GR, Charney DS. 1989a. The Yale-Brown Obsessive Compulsive Scale. II. Validity. Arch Gen Psychiatry 46: 1012-1016.
7. Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL, Heninger GR, Charney DS. 1989b. The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry 46:1006-1011.
8. Goodman WK, Price LH. 1998. Rating scales for obsessive-compulsive disorder. In: Jenike M, Baer L, Minichiello W, editors. Obsessive-compulsive disorders: Practical management. St. Louis: Mosby, Inc. p 97-117.
9. Guy W. 1976. ECDEU Assessment Manual for Psychopharmacology. Rockville, Maryland: US Department of Health, Education, and Welfare.
10. Hamilton M. 1960. A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56-62.
11. Hollander E, Allen A, Steiner M, Wheadon DE, Oakes R, Burnham DB. 2003. Acute and long-term treatment and prevention of relapse of obsessive-compulsive disorder with paroxetine. J Clin Psychiatry 64:1113-1121.
12. Hosmer DW, Lemeshow S. 1999. Applied survival analysis: Regression modeling of time to event data. New York: Wiley. 386 p.
13. Koran LM, Hackett E, Rubin A, Wolkow R, Robinson D. 2002. Efficacy of sertraline in the long-term treatment of obsessive-compulsive disorder. Am J Psychiatry 159:88-95.
14. Kordy H, Kramer B, Palmer RL, Papezova H, Pellet J, Richard M, Treasure J. 2002. Remission, recovery, relapse, and recurrence in eating disorders: Conceptualization and illustration of a validation strategy. J Clin Psychol 58:833-846.
15. Kozak MJ, Foa EB. 1997. Mastery of obsessive-compulsive disorder: A cognitive-behavioral approach. San Antonio, TX: The Psychological Corporation.
16. Leonard HL, Swedo SE, Rapoport JL, Koby EV, Lenane MC, Cheslow DL, Hamburger SD. 1989. Treatment of obsessive-compulsive disorder with clomipramine and desipramine in children and adolescents. A double-blind crossover comparison. Arch Gen Psychiatry 46:1088-1092.
17. Maina G, Albert U, Bogetto F. 2001. Relapses after discontinuation of drug associated with increased resistance to treatment in obsessive-compulsive disorder. Int Clin Psychopharmacol 16: 33-38.
18. Pallanti S, Hollander E, Bienstock C, Koran L, Leckman J, Marazziti D, Pato M, Stein D, Zohar J. 2002. Treatment non-response in OCD: Methodological issues and operational definitions. Int J Neuropsychopharmacol 5:181-191.
19. Pato MT, Zohar-Kadouch R, Zohar J, Murphy DL. 1988. Return of symptoms after discontinuation of clomipramine in patients with obsessive-compulsive disorder. Am J Psychiatry 145: 1521-1525.
20. Pigott TA, Seay SM. 1999. A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder. J Clin Psychiatry 60:101-106.
21. Ravizza L, Barzega G, Bellino S, Bogetto F, Maina G. 1996. Drug treatment of obsessive-compulsive disorder (OCD): Long-term trial with clomipramine and selective serotonin reuptake inhibitors (SSRIs). Psychopharmacol Bull 32:167-173.
22. Riso LP, Thase ME, Howland RH, Friedman ES, Simons AD, Tu XM. 1997. A prospective test of criteria for response, remission, relapse, recovery, and recurrence in depressed patients treated with cognitive behavior therapy. J Affect Disord 43:131-142.
23. Romano S, Goodman W, Tamura R, Gonzales J. 2001. Long-term treatment of obsessive-compulsive disorder after an acute response: A comparison of fluoxetine versus placebo. J Clin Psychopharmacol 21:46-52.
24. Simpson HB, Liebowitz MR, Foa EB, Kozak MJ, Schmidt AB, Rowan V, Petkova E, Kjernisted K, Huppert JD, Franklin ME, Davies SO, Campeas R. 2004. Post-treatment effects of exposure therapy versus clomipramine in OCD. Depress Anxiety 19: 225-233.